查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102980

泛自閉症障礙市場：策略性洞察與預測（2026-2035）

Autism Spectrum Disorder Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

根據《全球泛自閉症障礙市場分析》，預計該市場規模將從 2026 年的 282 億美元成長到 2035 年的 442 億美元，複合年成長率為 5.1%。

泛自閉症障礙是一種複雜的神經發展障礙，其特徵是社交溝通障礙、重複性行為以及多種認知和行為特徵。此障礙的嚴重程度和臨床表現差異很大，需要個別化的治療方法。雖然行為療法仍然是治療的基礎，但藥物療法、基於生物標記的診斷、數位健康解決方案和精準醫療的進步正在顯著地塑造未來的治療方向。

市場促進因素

自閉症診斷率上升

由於篩檢計畫的改進、診斷標準的擴展、醫生意識的提高以及公眾教育的加強，全球自閉症診斷數量持續上升。早期發現有助於及時干預，從而導致對自閉症相關醫療保健服務的需求日益成長。

擴大早期療育計劃

各國政府、醫療機構和教育機構持續擴大早期療育服務、行為治療計畫和多學科治療中心。早期療育能夠顯著改善發育結果，並且仍然是市場成長的主要驅動力。

加大神經發育研究的投資

公共和私人對神經科學、遺傳學和神經發育障礙的投資不斷增加，正在加速對自閉症創新療法、生物標記和個人化治療策略的研究。

精準醫療和數位療法的進展

人工智慧、數位行為監測、遠距醫療平台、穿戴式技術和生物標記研究正在改善診斷、病患監測和個人化治療計劃，從而支持市場擴張。

市場限制因素

已通過核准藥物療法的供應有限。

目前的治療方法主要著重於行為介入和症狀管理。能夠直接針對自閉症核心症狀的藥物很少，這限制了治療選擇。

行為干預成本高昂

長期行為治療、職業治療、語言治療和專業教育支援可能會對家庭和醫療保健系統造成沉重的經濟負擔。

勞動力短缺

在許多地區，訓練有素的行為治療師、發展專家、心理學家和自閉症護理專家仍然短缺，限制了患者在適當的時候獲得治療的機會。

目錄

第1章：執行摘要

  • 本報告的範圍和目標
  • 主要分析結果
  • 市場概述
  • 成長前景
  • 主要市場促進因素
  • 市場挑戰
  • 新的商機
  • 分析師意見

第2章：泛自閉症障礙市場概覽

  • 泛自閉症障礙概述
  • 疾病分類
    • 一級自閉症譜系障礙
    • 2級自閉症譜系障礙
    • 3級自閉症譜系障礙
    • 自閉症綜合症
    • 非症候群型自閉症
  • 疾病負擔評估
  • 患者進展分析
  • 目前治療狀態
  • 治療方面的新趨勢
  • 未滿足需求的評估
  • 市場趨勢概述

第3章 市場動態

  • 市場促進因素
    • 自閉症診斷率上升
    • 提高意識計劃
    • 擴大早期療育計劃
    • 醫療保健支出增加
    • 精準醫學的進展
  • 市場限制因素
    • 目前核准的藥物療法有限。
    • 行為干預的高成本
    • 與還款相關的挑戰
    • 勞動力短缺
  • 市場機遇
    • 新療法藥物的研發
    • 基於生物標記的患者分層
    • 數位療法的擴展
    • 個人化治療方案
  • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 市場規模及預測分析

  • 全球市場收益預測
  • 過往市場分析
  • 市場預測分析法
  • 基本案例預測情景
  • 樂觀情境
  • 保守預測情景
  • 絕對商機分析
  • 增量機會分析
  • 市場吸引力分析

第5章 市場區隔：依治療方法

  • 行為療法
    • 應用行為分析（ABA）
    • 早期強化行為介入（EIBI）
    • 認知行為治療（CBT）
    • 社交技能訓練
    • 銷售預測
  • 發育療法
    • 發展支持干預
    • 關係療法
    • 銷售預測
  • 語言治療
    • 服務使用趨勢
    • 銷售預測
  • 職業療法
    • 服務使用趨勢
    • 銷售預測
  • 教育干預
    • 特殊需求教育計劃
    • 校本介入
    • 收入預測
  • 藥物治療
    • 抗精神病藥物治療
    • 注意力不足過動症症狀管理療法
    • 焦慮和情緒管理療法
    • 銷售預測
  • 新興療法
    • 精準醫療方法
    • 以微生物組為基礎的療法
    • 新型神經發育療法
    • 銷售預測

第6章 市場區隔：依疾病嚴重程度分類

  • 一級自閉症譜系障礙
    • 市場規模
    • 預測分析
  • 二級泛自閉症障礙（ASD）
    • 市場規模
    • 預測分析
  • 3級自閉症譜系障礙
    • 市場規模
    • 預測分析

第7章 市場區隔：依疾病分類

  • 自閉症綜合症
    • 市場規模
    • 預測分析
  • 非症候群型自閉症
    • 市場規模
    • 預測分析

第8章 市場區隔：依年齡層

  • 兒童（0-12歲）
    • 市場規模
    • 預測分析
  • 青少年人口（13-17歲）
    • 市場規模
    • 預測分析
  • 成年人口（18歲以上）
    • 市場規模
    • 預測分析

第9章 市場區隔：依最終用戶分類

  • 醫院和專科診所
    • 市場規模
    • 預測分析
  • 自閉症治療中心
    • 市場規模
    • 預測分析
  • 復健中心
    • 市場規模
    • 預測分析
  • 教育機構
    • 市場規模
    • 預測分析
  • 居家照護機構
    • 市場規模
    • 預測分析

第10章 區域分析

  • 北美洲
    • 市場規模及預測
    • 治療引入趨勢
    • 贖回環境
    • 競爭格局
    • 發展機會
  • 歐洲
    • 市場規模及預測
    • 治療引入趨勢
    • 贖回環境
    • 競爭格局
    • 發展機會
  • 亞太地區
    • 市場規模及預測
    • 治療引入趨勢
    • 贖回環境
    • 競爭格局
    • 發展機會
  • 拉丁美洲
    • 市場規模及預測
    • 治療引入趨勢
    • 贖回環境
    • 競爭格局
    • 發展機會
  • 中東和非洲
    • 市場規模及預測
    • 治療引入趨勢
    • 贖回環境
    • 競爭格局
    • 發展機會

第11章 主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第12章 競爭格局

  • 市佔率分析
  • 競爭基準
  • 戰略定位矩陣
  • 管道競爭性評估
  • 夥伴關係與合作分析
  • 企業合併分析
  • 授權協議和共同開發契約
  • 未來競爭環境展望

第13章：公司簡介

  • Roche
  • Yamo Pharmaceuticals
  • Stalicla SA
  • Axial Therapeutics
  • SciSparc Ltd.
  • Oryzon Genomics SA
  • Curemark, LLC
  • Neurochlore SAS
  • Jazz Pharmaceuticals plc
  • Servier

第14章：評估市場機會

  • 總潛在市場規模（TAM）
  • 服務提供目標市場 (SAM)
  • 可提供及取得服務的市場（SOM）
  • 評估未接受治療患者的市場機會
  • 新興療法的機會分析
  • 區域機會評估
  • 投資機會分析

第15章 分析方法

  • 初步調查
  • 第二次調查
  • 建立市場模型分析方法
  • 預測分析方法
  • 數據檢驗和三角測量
  • 先決條件和限制

第16章附錄

簡介目錄
Product Code: KSI-008986

The Global Autism Spectrum Disorder Market Forecast Report is set to reach USD 44.2 billion in 2035, growing at a CAGR of 5.1% from USD 28.2 billion in 2026.

Autism Spectrum Disorder is a complex neurodevelopmental condition characterized by challenges in social communication, repetitive behaviors, and varying cognitive and behavioral characteristics. The disorder encompasses a broad spectrum of severity levels and clinical presentations, requiring individualized treatment approaches. While behavioral interventions remain the cornerstone of management, increasing research into pharmacological therapies, biomarker-guided diagnosis, digital health solutions, and precision medicine is transforming the future treatment landscape.

Market Drivers

Rising Autism Diagnosis Rates

Improved screening programs, broader diagnostic criteria, enhanced physician awareness, and greater public education continue to increase autism diagnosis worldwide. Earlier identification enables timely intervention and expands demand for autism-related healthcare services.

Expansion of Early Intervention Programs

Governments, healthcare providers, and educational institutions continue expanding early intervention services, behavioral therapy programs, and multidisciplinary treatment centers. Early intervention significantly improves developmental outcomes and remains a major driver of market growth.

Growing Investment in Neurodevelopmental Research

Increasing public and private investment in neuroscience, genetics, and neurodevelopmental disorders is accelerating research into innovative therapies, biomarkers, and personalized treatment strategies for autism.

Advances in Precision Medicine and Digital Therapeutics

Artificial intelligence, digital behavioral monitoring, teletherapy platforms, wearable technologies, and biomarker research are improving diagnosis, patient monitoring, and individualized treatment planning, supporting market expansion.

Market Restraints

Limited Approved Pharmacological Therapies

Current treatment primarily focuses on behavioral interventions and symptom management. Few medications directly address the core symptoms of autism, limiting therapeutic options.

High Cost of Behavioral Interventions

Long-term behavioral therapy, occupational therapy, speech therapy, and specialized educational support can create substantial financial burdens for families and healthcare systems.

Workforce Shortages

Many regions continue experiencing shortages of trained behavioral therapists, developmental specialists, psychologists, and autism care professionals, limiting timely access to treatment.

Market and Technology Insights

The global autism spectrum disorder market can be segmented by treatment type, disease classification, age group, end user, and geography.

By treatment type, the market includes behavioral therapies, Applied Behavior Analysis (ABA), Early Intensive Behavioral Intervention (EIBI), speech therapy, occupational therapy, pharmacological therapies, digital therapeutics, and other supportive interventions. Behavioral therapies continue to represent the largest market segment because they remain the primary standard of care for improving communication, social interaction, and adaptive functioning. Digital therapeutics and technology-assisted interventions are expected to experience rapid growth as healthcare systems increasingly adopt remote care and personalized treatment solutions.

By disease classification, the market includes Level 1 ASD, Level 2 ASD, Level 3 ASD, syndromic autism, and non-syndromic autism. Individualized treatment planning varies according to symptom severity and patient needs, with increasing emphasis on precision medicine and biologically defined patient subgroups.

By age group, the market comprises pediatric patients, adolescents, and adults. Pediatric patients account for the largest share because diagnosis most commonly occurs during early childhood and intervention is initiated at younger ages.

By end user, the market includes hospitals, specialty autism centers, rehabilitation clinics, educational institutions, home care settings, and community-based care providers. Specialized autism treatment centers continue expanding as multidisciplinary care models become more widely adopted.

Market Trends

The autism treatment landscape continues evolving through scientific innovation and personalized care.

Key trends include:

  • Expansion of precision medicine approaches.
  • Growing adoption of digital therapeutics.
  • Increased use of teletherapy and virtual behavioral interventions.
  • Rising investment in biomarker-based diagnostics.
  • Development of novel pharmacological therapies.
  • Greater use of artificial intelligence in diagnosis and patient monitoring.
  • Increasing focus on personalized treatment strategies.

Regional Insights

North America remains the largest autism spectrum disorder market because of high diagnosis rates, advanced healthcare infrastructure, strong reimbursement systems, extensive research funding, and widespread availability of behavioral intervention services.

Europe maintains a significant market share through comprehensive healthcare systems, increasing autism awareness, strong research collaboration, and government-supported intervention programs.

Asia-Pacific is expected to register the fastest growth owing to expanding healthcare infrastructure, improving diagnosis rates, rising public awareness, increasing healthcare expenditure, and growing investment in pediatric neurodevelopmental services.

Latin America and the Middle East & Africa continue improving autism care through expanding healthcare access, physician education, and increasing government initiatives supporting developmental disorder management.

Competitive Landscape

The autism spectrum disorder market includes pharmaceutical companies, biotechnology firms, behavioral healthcare providers, digital health companies, diagnostic technology developers, and specialized autism care organizations.

Organizations continue investing in behavioral therapies, digital therapeutics, biomarker research, precision medicine, artificial intelligence-enabled diagnostics, and novel pharmacological therapies. Strategic collaborations, licensing agreements, clinical partnerships, and research alliances continue accelerating innovation across the autism treatment ecosystem.

Future Outlook

The future of the autism spectrum disorder market will be shaped by advances in precision medicine, digital health technologies, biomarker-guided diagnosis, and personalized therapeutic approaches. Continued research into the biological mechanisms of autism, combined with improvements in early diagnosis and multidisciplinary care, is expected to expand treatment opportunities and improve long-term patient outcomes through 2035.

Conclusion

The Global Autism Spectrum Disorder Market is expected to experience sustained growth through 2035, supported by rising diagnosis rates, expanding early intervention programs, advances in neuroscience research, and increasing adoption of innovative treatment technologies. Although limited pharmacological therapies, reimbursement challenges, and workforce shortages remain significant barriers, continued innovation in behavioral interventions, digital therapeutics, and precision medicine is expected to create substantial opportunities for healthcare providers, pharmaceutical companies, biotechnology firms, and investors.

Key Benefits of this Report

  • Comprehensive analysis of the global autism spectrum disorder market.
  • Detailed evaluation of treatment modalities, technological innovations, and market trends.
  • Assessment of competitive strategies, emerging therapies, and commercialization opportunities.
  • Insights into diagnosis, patient management, reimbursement, and future growth drivers.
  • Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, consultants, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive intelligence, commercialization strategy, investment analysis, partnership evaluation, regulatory planning, healthcare service expansion, and long-term strategic decision-making.

Report Coverage

  • Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global autism spectrum disorder market by treatment type, disease classification, age group, end user, and geography
  • Evaluation of market dynamics, competitive landscape, treatment trends, technological innovations, regulatory environment, and future growth opportunities
  • Assessment of strategic collaborations, research and development activities, digital therapeutics, precision medicine, and commercialization strategies
  • Analysis of behavioral therapies, Applied Behavior Analysis (ABA), Early Intensive Behavioral Intervention (EIBI), speech therapy, occupational therapy, pharmacological therapies, digital therapeutics, biomarker-based diagnostics, and emerging treatment opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Report Scope and Objectives
  • 1.2 Key Findings
  • 1.3 Market Snapshot
  • 1.4 Growth Outlook (2025-2035)
  • 1.5 Key Market Drivers
  • 1.6 Market Challenges
  • 1.7 Emerging Opportunities
  • 1.8 Analyst Perspective

2. Autism Spectrum Disorder Market Overview

  • 2.1 Introduction to Autism Spectrum Disorder
  • 2.2 Disease Classification
    • 2.2.1 Level 1 ASD
    • 2.2.2 Level 2 ASD
    • 2.2.3 Level 3 ASD
    • 2.2.4 Syndromic Autism
    • 2.2.5 Non-Syndromic Autism
  • 2.3 Disease Burden Assessment
  • 2.4 Patient Journey Analysis
  • 2.5 Current Treatment Landscape
  • 2.6 Emerging Treatment Landscape
  • 2.7 Unmet Needs Assessment
  • 2.8 Market Evolution Overview

3. Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Rising Autism Diagnosis Rates
    • 3.1.2 Increasing Awareness Programs
    • 3.1.3 Expansion of Early Intervention Programs
    • 3.1.4 Growing Healthcare Expenditure
    • 3.1.5 Advancements in Precision Medicine
  • 3.2 Market Restraints
    • 3.2.1 Limited Approved Pharmacological Therapies
    • 3.2.2 High Cost of Behavioral Interventions
    • 3.2.3 Reimbursement Challenges
    • 3.2.4 Workforce Shortages
  • 3.3 Market Opportunities
    • 3.3.1 Novel Therapeutic Development
    • 3.3.2 Biomarker-Based Patient Stratification
    • 3.3.3 Digital Therapeutics Expansion
    • 3.3.4 Personalized Treatment Approaches
  • 3.4 Market Challenges
  • 3.5 Porter's Five Forces Analysis
  • 3.6 PESTLE Analysis

4. Market Size and Forecast Analysis (2025-2035)

  • 4.1 Global Market Revenue Forecast
  • 4.2 Historical Market Analysis (2021-2024)
  • 4.3 Market Forecast Methodology
  • 4.4 Base Case Forecast Scenario
  • 4.5 Optimistic Forecast Scenario
  • 4.6 Conservative Forecast Scenario
  • 4.7 Absolute Dollar Opportunity Analysis
  • 4.8 Incremental Revenue Opportunity Analysis
  • 4.9 Market Attractiveness Analysis

5. Market Segmentation by Treatment Type

  • 5.1 Behavioral Therapies
    • 5.1.1 Applied Behavior Analysis (ABA)
    • 5.1.2 Early Intensive Behavioral Intervention (EIBI)
    • 5.1.3 Cognitive Behavioral Therapy (CBT)
    • 5.1.4 Social Skills Training
    • 5.1.5 Revenue Forecast (2025-2035)
  • 5.2 Developmental Therapies
    • 5.2.1 Developmental Interventions
    • 5.2.2 Relationship-Based Therapies
    • 5.2.3 Revenue Forecast (2025-2035)
  • 5.3 Speech and Language Therapy
    • 5.3.1 Service Utilization Trends
    • 5.3.2 Revenue Forecast (2025-2035)
  • 5.4 Occupational Therapy
    • 5.4.1 Service Utilization Trends
    • 5.4.2 Revenue Forecast (2025-2035)
  • 5.5 Educational Interventions
    • 5.5.1 Special Education Programs
    • 5.5.2 School-Based Interventions
    • 5.5.3 Revenue Forecast (2025-2035)
  • 5.6 Pharmacological Therapies
    • 5.6.1 Antipsychotic Therapies
    • 5.6.2 ADHD Symptom Management Therapies
    • 5.6.3 Anxiety and Mood Management Therapies
    • 5.6.4 Revenue Forecast (2025-2035)
  • 5.7 Emerging Therapies
    • 5.7.1 Precision Medicine Approaches
    • 5.7.2 Microbiome-Based Therapies
    • 5.7.3 Novel Neurodevelopmental Therapies
    • 5.7.4 Revenue Forecast (2025-2035)

6. Market Segmentation by Disease Severity

  • 6.1 Level 1 ASD
    • 6.1.1 Market Size
    • 6.1.2 Forecast Analysis
  • 6.2 Level 2 ASD
    • 6.2.1 Market Size
    • 6.2.2 Forecast Analysis
  • 6.3 Level 3 ASD
    • 6.3.1 Market Size
    • 6.3.2 Forecast Analysis

7. Market Segmentation by Disease Type

  • 7.1 Syndromic Autism
    • 7.1.1 Market Size
    • 7.1.2 Forecast Analysis
  • 7.2 Non-Syndromic Autism
    • 7.2.1 Market Size
    • 7.2.2 Forecast Analysis

8. Market Segmentation by Age Group

  • 8.1 Pediatric Population (0-12 Years)
    • 8.1.1 Market Size
    • 8.1.2 Forecast Analysis
  • 8.2 Adolescent Population (13-17 Years)
    • 8.2.1 Market Size
    • 8.2.2 Forecast Analysis
  • 8.3 Adult Population (18 Years and Above)
    • 8.3.1 Market Size
    • 8.3.2 Forecast Analysis

9. Market Segmentation by End User

  • 9.1 Hospitals and Specialty Clinics
    • 9.1.1 Market Size
    • 9.1.2 Forecast Analysis
  • 9.2 Autism Treatment Centers
    • 9.2.1 Market Size
    • 9.2.2 Forecast Analysis
  • 9.3 Rehabilitation Centers
    • 9.3.1 Market Size
    • 9.3.2 Forecast Analysis
  • 9.4 Educational Institutions
    • 9.4.1 Market Size
    • 9.4.2 Forecast Analysis
  • 9.5 Home-Based Care Settings
    • 9.5.1 Market Size
    • 9.5.2 Forecast Analysis

10. Geographical Analysis

  • 10.1 North America
    • 10.1.1 Market Size and Forecast
    • 10.1.2 Treatment Adoption Trends
    • 10.1.3 Reimbursement Environment
    • 10.1.4 Competitive Landscape
    • 10.1.5 Growth Opportunities
  • 10.2 Europe
    • 10.2.1 Market Size and Forecast
    • 10.2.2 Treatment Adoption Trends
    • 10.2.3 Reimbursement Environment
    • 10.2.4 Competitive Landscape
    • 10.2.5 Growth Opportunities
  • 10.3 Asia-Pacific
    • 10.3.1 Market Size and Forecast
    • 10.3.2 Treatment Adoption Trends
    • 10.3.3 Reimbursement Environment
    • 10.3.4 Competitive Landscape
    • 10.3.5 Growth Opportunities
  • 10.4 Latin America
    • 10.4.1 Market Size and Forecast
    • 10.4.2 Treatment Adoption Trends
    • 10.4.3 Reimbursement Environment
    • 10.4.4 Competitive Landscape
    • 10.4.5 Growth Opportunities
  • 10.5 Middle East & Africa
    • 10.5.1 Market Size and Forecast
    • 10.5.2 Treatment Adoption Trends
    • 10.5.3 Reimbursement Environment
    • 10.5.4 Competitive Landscape
    • 10.5.5 Growth Opportunities

11. Key Countries Analysis

  • 11.1 United States
    • 11.1.1 Market Size and Forecast
    • 11.1.2 Treatment Adoption Trends
    • 11.1.3 Reimbursement Environment
    • 11.1.4 Competitive Landscape
    • 11.1.5 Growth Opportunities
  • 11.2 Canada
    • 11.2.1 Market Size and Forecast
    • 11.2.2 Treatment Adoption Trends
    • 11.2.3 Reimbursement Environment
    • 11.2.4 Competitive Landscape
    • 11.2.5 Growth Opportunities
  • 11.3 Germany
    • 11.3.1 Market Size and Forecast
    • 11.3.2 Treatment Adoption Trends
    • 11.3.3 Reimbursement Environment
    • 11.3.4 Competitive Landscape
    • 11.3.5 Growth Opportunities
  • 11.4 United Kingdom
    • 11.4.1 Market Size and Forecast
    • 11.4.2 Treatment Adoption Trends
    • 11.4.3 Reimbursement Environment
    • 11.4.4 Competitive Landscape
    • 11.4.5 Growth Opportunities
  • 11.5 France
    • 11.5.1 Market Size and Forecast
    • 11.5.2 Treatment Adoption Trends
    • 11.5.3 Reimbursement Environment
    • 11.5.4 Competitive Landscape
    • 11.5.5 Growth Opportunities
  • 11.6 Italy
    • 11.6.1 Market Size and Forecast
    • 11.6.2 Treatment Adoption Trends
    • 11.6.3 Reimbursement Environment
    • 11.6.4 Competitive Landscape
    • 11.6.5 Growth Opportunities
  • 11.7 Spain
    • 11.7.1 Market Size and Forecast
    • 11.7.2 Treatment Adoption Trends
    • 11.7.3 Reimbursement Environment
    • 11.7.4 Competitive Landscape
    • 11.7.5 Growth Opportunities
  • 11.8 China
    • 11.8.1 Market Size and Forecast
    • 11.8.2 Treatment Adoption Trends
    • 11.8.3 Reimbursement Environment
    • 11.8.4 Competitive Landscape
    • 11.8.5 Growth Opportunities
  • 11.9 Japan
    • 11.9.1 Market Size and Forecast
    • 11.9.2 Treatment Adoption Trends
    • 11.9.3 Reimbursement Environment
    • 11.9.4 Competitive Landscape
    • 11.9.5 Growth Opportunities
  • 11.10 India
    • 11.10.1 Market Size and Forecast
    • 11.10.2 Treatment Adoption Trends
    • 11.10.3 Reimbursement Environment
    • 11.10.4 Competitive Landscape
    • 11.10.5 Growth Opportunities
  • 11.11 South Korea
    • 11.11.1 Market Size and Forecast
    • 11.11.2 Treatment Adoption Trends
    • 11.11.3 Reimbursement Environment
    • 11.11.4 Competitive Landscape
    • 11.11.5 Growth Opportunities
  • 11.12 Australia
    • 11.12.1 Market Size and Forecast
    • 11.12.2 Treatment Adoption Trends
    • 11.12.3 Reimbursement Environment
    • 11.12.4 Competitive Landscape
    • 11.12.5 Growth Opportunities

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Competitive Benchmarking
  • 12.3 Strategic Positioning Matrix
  • 12.4 Pipeline Competitiveness Assessment
  • 12.5 Partnership and Collaboration Analysis
  • 12.6 Mergers and Acquisitions Analysis
  • 12.7 Licensing and Co-Development Agreements
  • 12.8 Future Competitive Outlook

13. Company Profiles

  • 13.1 Roche
    • 13.1.1 Overview
    • 13.1.2 Financials
    • 13.1.3 Autism Spectrum Disorder Portfolio Overview
    • 13.1.4 Clinical Development Strategy
    • 13.1.5 Key Drug Candidates
    • 13.1.6 Commercial Strategy
    • 13.1.7 Strategic Collaborations
    • 13.1.8 Recent Developments
  • 13.2 Yamo Pharmaceuticals
    • 13.2.1 Overview
    • 13.2.2 Financials
    • 13.2.3 Autism Spectrum Disorder Portfolio Overview
    • 13.2.4 Clinical Development Strategy
    • 13.2.5 Key Drug Candidates
    • 13.2.6 Commercial Strategy
    • 13.2.7 Strategic Collaborations
    • 13.2.8 Recent Developments
  • 13.3 Stalicla SA
    • 13.3.1 Overview
    • 13.3.2 Financials
    • 13.3.3 Autism Spectrum Disorder Portfolio Overview
    • 13.3.4 Clinical Development Strategy
    • 13.3.5 Key Drug Candidates
    • 13.3.6 Commercial Strategy
    • 13.3.7 Strategic Collaborations
    • 13.3.8 Recent Developments
  • 13.4 Axial Therapeutics
    • 13.4.1 Overview
    • 13.4.2 Financials
    • 13.4.3 Autism Spectrum Disorder Portfolio Overview
    • 13.4.4 Clinical Development Strategy
    • 13.4.5 Key Drug Candidates
    • 13.4.6 Commercial Strategy
    • 13.4.7 Strategic Collaborations
    • 13.4.8 Recent Developments
  • 13.5 SciSparc Ltd.
    • 13.5.1 Overview
    • 13.5.2 Financials
    • 13.5.3 Autism Spectrum Disorder Portfolio Overview
    • 13.5.4 Clinical Development Strategy
    • 13.5.5 Key Drug Candidates
    • 13.5.6 Commercial Strategy
    • 13.5.7 Strategic Collaborations
    • 13.5.8 Recent Developments
  • 13.6 Oryzon Genomics S.A.
    • 13.6.1 Overview
    • 13.6.2 Financials
    • 13.6.3 Autism Spectrum Disorder Portfolio Overview
    • 13.6.4 Clinical Development Strategy
    • 13.6.5 Key Drug Candidates
    • 13.6.6 Commercial Strategy
    • 13.6.7 Strategic Collaborations
    • 13.6.8 Recent Developments
  • 13.7 Curemark, LLC
    • 13.7.1 Overview
    • 13.7.2 Financials
    • 13.7.3 Autism Spectrum Disorder Portfolio Overview
    • 13.7.4 Clinical Development Strategy
    • 13.7.5 Key Drug Candidates
    • 13.7.6 Commercial Strategy
    • 13.7.7 Strategic Collaborations
    • 13.7.8 Recent Developments
  • 13.8 Neurochlore SAS
    • 13.8.1 Overview
    • 13.8.2 Financials
    • 13.8.3 Autism Spectrum Disorder Portfolio Overview
    • 13.8.4 Clinical Development Strategy
    • 13.8.5 Key Drug Candidates
    • 13.8.6 Commercial Strategy
    • 13.8.7 Strategic Collaborations
    • 13.8.8 Recent Developments
  • 13.9 Jazz Pharmaceuticals plc
    • 13.9.1 Overview
    • 13.9.2 Financials
    • 13.9.3 Autism Spectrum Disorder Portfolio Overview
    • 13.9.4 Clinical Development Strategy
    • 13.9.5 Key Drug Candidates
    • 13.9.6 Commercial Strategy
    • 13.9.7 Strategic Collaborations
    • 13.9.8 Recent Developments
  • 13.10 Servier
    • 13.10.1 Overview
    • 13.10.2 Financials
    • 13.10.3 Autism Spectrum Disorder Portfolio Overview
    • 13.10.4 Clinical Development Strategy
    • 13.10.5 Key Drug Candidates
    • 13.10.6 Commercial Strategy
    • 13.10.7 Strategic Collaborations
    • 13.10.8 Recent Developments

14. Market Opportunity Assessment

  • 14.1 Total Addressable Market (TAM)
  • 14.2 Serviceable Addressable Market (SAM)
  • 14.3 Serviceable Obtainable Market (SOM)
  • 14.4 Untreated Patient Opportunity Assessment
  • 14.5 Emerging Therapy Opportunity Analysis
  • 14.6 Regional Opportunity Assessment
  • 14.7 Investment Opportunity Analysis

15. Research Methodology

  • 15.1 Primary Research
  • 15.2 Secondary Research
  • 15.3 Market Modeling Methodology
  • 15.4 Forecasting Methodology
  • 15.5 Data Validation and Triangulation
  • 15.6 Assumptions and Limitations

16. Appendix

  • 16.1 Abbreviations
  • 16.2 Glossary of Terms
  • 16.3 References
  • 16.4 List of Tables
  • 16.5 List of Figures
  • 16.6 Clinical Literature Sources
  • 16.7 Company Sources
  • 16.8 Healthcare Organization Sources
  • 16.9 Market Data Sources